Rienso®▼ (ferumoxytol) Receives European Marketing Authorisation for the Treatment of Iron Deficiency Anaemia in Adult Chronic Kidney Disease Patients

Rienso®▼ (ferumoxytol) Receives European Marketing Authorisation for the Treatment of Iron Deficiency Anaemia in Adult Chronic Kidney Disease Patients PR Newswire LONDON, OSAKA, Japan and LEXINGTON, Massachusetts, June 22, 2012 LONDON, OSAKA, Japan and LEXINGTON, Massachusetts, June 22, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) and AMAG Pharmaceuticals, Inc. today announced the granting of marketing authorisation by the European Commission (EC) for ferumoxytol, a new intravenous (IV) iron therapy to treat iron deficiency anaemia (IDA) in adult patients with chronic kidney disease (CKD). The marketing authorisation follows a positive opinion issued on April 19, 2012, by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). With receipt of the EC decision, Takeda intends to launch ferumoxytol across Europe in the near future. "The granting of European marketing authorisation for ferumoxytol marks an important milestone for Takeda in our ongoing commitment to the field of renal medicine. We look forward to providing ferumoxytol, a valuable new therapeutic option, to clinicians in the near future" said Trevor Smith, Head of Commercial Operations, Europe & Canada, Takeda Pharmaceuticals.